Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock held $3.5M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
CYCCP Debt & Cash by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $3.5M+11.7% | $3.1M-7.1% | $3.4M-81.6% | $18.3M-49.8% | $36.6M+9.4% | $33.4M+181.1% | $11.9M-32.1% | $17.5M-26.8% | $23.9M+44.7% | $16.5M-19.2% | $20.4M-15.5% | $24.2M-22.3% | $31.1M+89.8% | $16.4M-32.9% | $24.4M |
CYCCP Debt & Cash by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $3.3M-3.2% | $3.5M+11.7% | $3.8M+28.7% | $4.3M-28.7% | $3.5M+23.3% | $3.1M-7.1% | $3.0M-49.8% | $6.0M-41.0% | $2.8M-75.5% | $3.4M-81.6% | $5.9M-74.9% | $10.2M-65.0% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock financials
Frequently Asked Questions
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock held $3.5M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) reported on that line in every period on record.